SCM
AVNR

Sterling Capital Management’s AVANIR PHARMACEUTICALS, INC CL A AVNR Stock Holding History

Sterling Capital Management’s Portfolio AVNR Stock Details AVNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-23,049
Closed -$275K – 1012
2014
Q3 		$275K Buy
+23,049
New +$157K ﹤0.01% 830

Other funds holding AVNR

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Sterling Capital Management's AVNR Position: Q4 2014 in Review

Sterling Capital Management sold out of AVANIR PHARMACEUTICALS, INC CL A (AVNR) in Q4 2014, closing a stake of 23,049 shares — an estimated $275K sold.

Sterling Capital Management first reported a position in AVNR in Q3 2014 and held it in 1 quarter. The position peaked at $275K in Q3 2014. 166 funds tracked by Wall St. Rank hold AVNR as of Q4 2014.

  • Sterling Capital Management reported no remaining AVANIR PHARMACEUTICALS, INC CL A position as of Q4 2014 after selling out during the quarter.
  • Sterling Capital Management sold 23,049 AVANIR PHARMACEUTICALS, INC CL A shares in Q4 2014, an estimated $275K.
  • Sterling Capital Management first reported a position in AVANIR PHARMACEUTICALS, INC CL A in Q3 2014 and held it in 1 quarter.
  • Sterling Capital Management's AVANIR PHARMACEUTICALS, INC CL A position peaked at $275K in Q3 2014.
  • 166 funds tracked by Wall St. Rank held AVANIR PHARMACEUTICALS, INC CL A as of Q4 2014.

Based on Sterling Capital Management's 13F filing for Q4 2014, filed 13 Feb 2015.